FDA Cites Dabur India Limited in 2026-07-24 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
At a glance: FDA Center for Drug Evaluation and Research (CDER) issued Warning Letter 320-26-105 to Dabur India Limited (FEI 3001413302, Silvassa facility) on July 24, 2026, following a January 12-16, 2026 inspection, citing CGMP violations for finished pharmaceuticals under 21 CFR parts 210 and 211. Violations include: inadequate quality control unit authority and oversight; falsification of equipment usage logbooks for OTC drug product lines; and discrepancies between source analytical data and reported batch records/certificates of analysis for quality attributes (residue on ignition, melting range, pH, viscosity) across multiple batches. FDA deemed the company's February 4, 2026 response inadequate because corrective actions treated data integrity failures as isolated procedural gaps rather than systemic quality culture breakdown, and failed to assess potential impact on distributed U.S. market products or adequately evaluate QU capability.
Argus analysis
# FDA Warning Letter Analysis: Dabur India Limited
**Company and Violations**
Dabur India Limited, a pharmaceutical manufacturer operating in Silvassa, India (FEI 3001413302), received a warning letter from the FDA's Center for Drug Evaluation and Research on July 24, 2026, following an inspection conducted January 12–16, 2026. The FDA found the facility failed to maintain adequate current good manufacturing practices (CGMP) for finished over-the-counter pharmaceuticals, rendering products adulterated. Core findings included falsified production records, missing laboratory documentation, and data discrepancies between source records and reported analytical results across multiple batches.
**Regulatory Citations and Implications**
The warning letter cites 21 CFR parts 210 and 211, which establish CGMP standards for pharmaceutical manufacturing. Specifically, 21 CFR 211.22(a) requires a quality control unit with documented authority to approve or reject materials and products; 21 CFR 211.194(a) mandates complete laboratory records for all tests performed. The FDA emphasized that missing microbiological plates, absent test procedures, and transcription errors between analytical notebooks and batch records violated data integrity expectations. These violations suggest systemic control failures rather than isolated procedural lapses, compromising the reliability of safety and quality claims for distributed U.S. products.
**Timeline and Monitoring Points**
Dabur submitted a response on February 4, 2026, which the FDA deemed inadequate. The company must now provide comprehensive corrective action and preventive action (CAPA) plans addressing documentation systems, quality unit capability and oversight, and a third-party investigation into data integrity scope. Compliance officers should monitor whether Dabur engages independent consultants, conducts retrospective batch testing of products still in distribution, and demonstrates sustained governance improvements. Subsequent FDA communications or import alerts would signal enforcement escalation.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Dabur India Limited MARCS-CMS 728828 — July 24, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-105 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Mohit Malhotra Recipient Title Chief Executive Officer Dabur India Limited Dabur Corporate Office, Kaushambi Sahibabad Ghaziabad 201010 India Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-105 July 24, 2026 Dear Mr. Malhotra: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Dabur India Limited, FEI 3001413302, at Survey No. 225/4/1, Village: Saily, Silvassa, Dadra and Nagar Haveli and Daman and Diu, from January 12 to 16, 2026. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your February 4, 2026 response to our Form FDA 483 in detail. During our inspection, our investigator observed specific violations including, but not limited to, the following. 1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated (21 CFR 211.22(a)). Your firm manufactures over-the-counter drug products including (b)(4) and (b)(4) . Your quality unit (QU) failed to exercise its authority and responsibilities over your drug manufacturing operations, including ensuring the integrity of your production records. During the inspection, our investigator requested the equipment usage logbook for Unit (b)(4) , Line (b)(4) , which your management stated was dedicated exclusively to (b)(4) manufacturing. Your firm delayed providing this record for several days. When your firm finally produced the logbook, it appeared to have been newly created. Subsequently, our investigator discovered the original logbook in the document room. A comparison of the two logbooks revealed that the version provided to our investigator was falsified. The fraudulent logbook listed entries only for (b)(4) . It deliberately omitted multiple U.S. marketed OTC drug products that were documented in the original logbook, including (b)(4) . Furthermore, our investigator identified multiple discrepancies between the …
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Dabur India Limited had FDA enforcement actions before?
- Yes. Argus HQ has recorded 16 total FDA actions tied to Dabur India Limited: 1 warning letter, 14 recalls, and 0 approval records.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Dabur India Limited in 2026-07-24 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-dabur-india-limited-2026-07-24-cgmp
"FDA Cites Dabur India Limited in 2026-07-24 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-dabur-india-limited-2026-07-24-cgmp.
Argus HQ Research. "FDA Cites Dabur India Limited in 2026-07-24 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed August 5, 2026. https://argushq.ai/fda/warning-letter/fda-wl-dabur-india-limited-2026-07-24-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_dabur_india_limited_2026_07_24_cgmp_2026,
title = {FDA Cites Dabur India Limited in 2026-07-24 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-dabur-india-limited-2026-07-24-cgmp},
note = {Accessed: August 5, 2026}
}